Article

AHA Statement Offers Advice on Treating Deep Vein Thrombosis

The AHA is encouraging doctors to consider therapies in addition to blood thinners to treat certain patients with potentially dangerous DVT.

Doctors are encouraged to consider therapies in addition to blood thinners to treat certain patients with potentially dangerous deep vein thrombosis (DVT), according to a new scientific statement from the American Heart Association. The statement is published online in Circulation: Journal of the American Heart Association.

More than 250,000 people in the United States are hospitalized with DVT each year. Previously, there has been limited guidance for physicians on some of the more serious conditions caused by DVT.

The statement offers advice for cardiologists and a range of other physicians who treat the disorder. Guidance is provided for identifying and treating people with massive and submassive pulmonary embolism, iliofemoral deep vein thrombosis, and chronic thromboembolic pulmonary hypertension.

“It is important for doctors to be able to identify the severity of these disorders and to select who might be eligible for more invasive therapies, such as clot-busting drugs, catheter-based treatments, or surgery,” said M. Sean McMurtry, MD, co-chair of the statement writing group. “Venous thromboembolism is very common and frequently a complication of other ailments. While most patients need blood thinners only, patients with more severe forms of venous thromboembolism may benefit from more aggressive treatments,” he said in a news release.

The statement outlines multiple treatment options including the use of fibrinolytic drugs, catheter-based interventions, treatment with surgery to remove the blood clots, and use of filters that prevent clots from traveling in the veins from the legs to the lungs, where they can cause strain on the heart. Additional guidance for treating pediatric patients is also included.

HCPLive wants to know:

Do you agree with the AHA's new scientific statement?Do you see it changing how you practice medicine?Do you agree that patients with more severe forms of venous thromboembolism may benefit from more aggressive treatments?Leave a comment below!

Related Videos
The APAC Recap: Cardiomyopathy at CAPP Live 2024 with Greg Duck, PA-C | Image Credit: APAC
The APAC Recap: Peripheral Artery Disease at CAPP Live 2024 with Bob Ross, PA-C | Image Credit: APAC
AMG0001 Advances Healing in CLTI with David G. Armstrong, DPM, PhD, and Michael S. Conte, MD | Image Credit: Canva
Brigit Vogel, MD: Exploring Geographical Disparities in PAD Care Across US| Image Credit: LinkedIn
| Image Credit: X
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Stephen Nicholls, MBBS, PhD | Credit: Monash University
Marianna Fontana, MD, PhD: Nex-Z Shows Promise in ATTR-CM Phase 1 Trial | Image Credit: Radcliffe Cardiology
Zerlasiran Achieves Durable Lp(a) Reductions at 60 Weeks, with Stephen J. Nicholls, MD, PhD | Image Credit: Monash University
© 2024 MJH Life Sciences

All rights reserved.